Abstract
LKB1, mutated in Peutz–Jeghers and in sporadic lung tumours, phosphorylates a group of protein kinases named AMP-activated protein kinase (AMPK)-related kinases. Among them is included the AMPK, a sensor of cellular energy status. To investigate the relevance of LKB1 in lung carcinogenesis, we study several lung cancer cells with and without LKB1-inactivating mutations. We report that LKB1-mutant cells are deficient for AMPK activity and refractory to mTOR inhibition upon glucose depletion but not growth-factor deprivation. The requirement for wild-type LKB1 to properly activate AMPK is further demonstrated in genetically modified cancer cells. In addition, LKB1-deficient lung primary tumours had diminished AMPK activity, assessed by complete absence or low level of phosphorylation of its critical substrate, acetyl-CoA carboxylase. We also demonstrate that LKB1 wild-type cells are more resistant to cell death upon glucose withdrawal than their mutant counterparts. Finally, modulation of AMPK activity did not affect PI3K/AKT signalling, an advantage for the potential use of AMPK as a target for cancer therapy in LKB1 wild-type tumours. Thus, sustained abrogation of cell energetic checkpoint control, through alterations at key genes, appear to be an obligatory step in the development of some lung tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA et al. (2003). Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 22: 3062–3072.
Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ et al. (2004). Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 116: 457–466.
Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M et al. (2003). MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22: 5102–5114.
Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E et al. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2804–2893.
Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL et al. (2005). The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165–4173.
Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M . (2004). Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23: 4037–4040.
Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A et al. (2006). Molecular context of the epidermal growth factor receptor mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12: 710–717.
Consortium TECS . (1993). Identification and characterization of the tuberous sclerosis gene 2 on chromosome 16. Cell 75: 1305–1315.
Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL . (2004). Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz–Jeghers syndrome. Genes Dev 18: 1533–1538.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892–3899.
Fernandez P, Carretero J, Medina PP, Jimenez AI, Rodriguez-Perales S, Paz MF et al. (2004). Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene 23: 5084–5091.
Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV et al. (1987). Increased risk of cancer in the Peutz–Jeghers syndrome. N Engl J Med 316: 1511–1514.
Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N . (2005). Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081–33209.
Hardie DG . (2003). The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179–5183.
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP et al. (2003). Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2: 28.
Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM et al. (2005). Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2: 9–19.
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. (1998). A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. Nature 18: 184–187.
Inoki K, Zhu T, Guan KL . (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577–590.
Jeghers H, McKusic VA, Katz KH . (1949). Generalized intestinal polyposis and melanin spots of the oral mucosa, lip, and digits: a syndrome of diagnostic significance. N Engl J Med 241: 1031–1036.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al. (1998). Peutz–Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18: 38–44.
Jimenez AI, Fernandez P, Dominguez O, Dopazo A, Sanchez-Cespedes M . (2003). Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3′-phosphate kinase/PTEN pathway. Cancer Res 63: 1382–1388.
Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R et al. (2001). The Peutz–Jeghers gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 7: 1307–1319.
Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M et al. (2002). Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 21: 6082–6090.
Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J et al. (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833–843.
Manning BD . (2004). Balancing AKT with S6K: implication for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399–403.
Manning BD, Cantley LC . (2003). United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31: 573–578.
Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LW . (2005). Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes & Dev 19: 1773–1778.
Mason DY, Cordell JL, Pulford KAF . (1983). Techniques in Immunocytochemistry. London Academic Press: London, p 17.
Nakau M, Miyosh H, Seldin MF, Imamura M, Oshima M, Taketo MM . (2002). Hepatocellular carcinoma caused by loss of heterozygosity in lkb1 gene knockout mice. Cancer Res 62: 4549–4553.
O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.
Plas DR, Thompson CB . (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435–7442.
Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V et al. (2002). Induction of cyclooxygenase-2 in a mouse model of Peutz–Jeghers polyposis. Proc Natl Acad Sci USA 99: 12327–12332.
Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659–3662.
Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA et al. (2004a). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91–99b.
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. (2004b). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329–3335a.
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052–7058.
Tiainen M, Ylikorkala A, Makela TP . (1999). Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA 96: 9248–9251.
Tzatsos A, Kandror KV . (2006). Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63–76.
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D et al. (2003). LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004–2008.
Ylikorkala A, Rossi DJ, Korsisaari N, Luukko K, Alitalo K, Henkemeyer M et al. (2001). Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science 293: 1323–1326.
Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Clin Invest 112: 1223–1233.
Acknowledgements
We thank our collaborators in the Tumour Bank Network. We also acknowledge the technical help of the Confocal Microscopy and Flow Cytometry, Immunohistochemistry and Protein Technology Units of the CNIO. The work was supported by the Spanish Ministerio de EducaciĂłn (SAF2005-00626). M Sanchez-Cespedes is supported by the Ramon y Cajal Programme and PP Medina by the Comunidad Autonoma de Madrid; R Blanco is supported by the Fondo de Investigaciones Sanitarias (FIS).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Carretero, J., Medina, P., Blanco, R. et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26, 1616–1625 (2007). https://doi.org/10.1038/sj.onc.1209951
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209951
Keywords
This article is cited by
-
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
Journal of Experimental & Clinical Cancer Research (2024)
-
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis
Signal Transduction and Targeted Therapy (2023)
-
HPV18 oncoproteins driven expression of PKM2 reprograms HeLa cell metabolism to maintain aerobic glycolysis and viability
VirusDisease (2022)
-
The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases
Inflammopharmacology (2022)
-
Adaptation of AMPK-mTOR-signal pathways and lipid metabolism in response to low- and high-level rapeseed meal diet in Chinese perch (Siniperca chuatsi)
Journal of Comparative Physiology B (2021)